Anthropic Targets AI-Driven Biology with gget Virus Tool
Anthropic, the $965 billion private AI powerhouse, is tackling a major bottleneck in biological research: the lack of agent-friendly data infrastructure. In a recent research post by Laura Luebbert, the company unveiled gget virus, a tool designed to improve the accuracy and reliability of AI agents in retrieving and processing biological data, starting with viral sequences. This move underscores Anthropic's ambitions to extend its AI expertise into science and healthcare.
Current biological data systems, such as NCBI Virus, are notoriously difficult for AI agents to navigate. They often require manual operation through complex web interfaces, making automation unreliable. Anthropic’s research team tested leading AI agents—including Claude models, GPT-5.5, and others—on viral sequence retrieval tasks using a benchmark called VirBench. Without gget virus, even state-of-the-art models achieved inconsistent results, with accuracy ranging from 16.9% to 91.3%. In some cases, agents produced wildly different outputs when asked the same question multiple times, a fatal flaw for scientific applications where precision is non-negotiable.
Enter gget virus. Acting as a deterministic retrieval layer, this tool consolidates data from fragmented biological resources and streamlines complex filtering directly within AI workflows. When agents were given access to gget virus, accuracy jumped to 99.7% for top-tier models like GPT-5.5, while variability in results nearly vanished. By standardizing outputs and logging retrieval processes, gget virus provides a new level of reproducibility crucial for tasks like outbreak response and drug development.
The tool’s immediate relevance was highlighted by the ongoing Bundibugyo virus outbreak in the Democratic Republic of Congo. Researchers relied on NCBI Virus to analyze viral genomes and assess existing diagnostic and therapeutic effectiveness. Without streamlined data retrieval, these life-or-death workflows depend on error-prone manual processes. Anthropic's tool could redefine how quickly and accurately such data is accessed during public health crises.
This development aligns with Anthropic's broader trajectory as a leader in AI innovation. The company, founded in 2021 by ex-OpenAI executives, has aggressively scaled its operations and valuation. As of May 2026, Anthropic raised $65 billion in a Series H round, valuing it at $965 billion, surpassing OpenAI in private market worth. With annualized revenue reportedly at $47 billion, Anthropic is now preparing for an IPO, having submitted a draft registration statement to U.S. regulators on June 1, 2026.
Anthropic’s push into biology also signals a strategic expansion beyond its flagship AI models under the Claude brand. The company has already faced scrutiny for loosening its AI safety commitments earlier this year, but its foray into healthcare and science could help bolster its reputation as a responsible innovator. Tools like gget virus showcase not just AI’s potential but also the real-world challenges it must overcome to integrate seamlessly into critical sectors.
Looking ahead, Anthropic’s biological data initiatives could pave the way for broader adoption of AI in science. However, as Luebbert noted, even as AI models improve, the need for deterministic tools like gget virus remains. These tools ensure that scientific workflows are not just automated but also trustworthy and accessible to a wider range of researchers, regardless of their access to cutting-edge AI models.
With Anthropic reportedly inching toward a trillion-dollar valuation and a high-profile IPO on the horizon, its success in reshaping biological data infrastructure could become a key narrative in its market positioning. Investors and researchers alike will be watching closely as the company attempts to balance AI innovation with real-world impact.